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Abstract
Background: Mycoplasma pneumoniae and Chlamydophila pneumoniae are major causes of lower
and upper respiratory infections that are difficult to diagnose using conventional methods such as
culture. The ProPneumo-1 (Prodesse, Waukesha, WI) assay is a commercial multiplex real-time
PCR assay for the simultaneous detection of M. pneumoniae and/or C. pneumoniae DNA in clinical
respiratory samples.
Objective: The aim of this study was to evaluate the sensitivity and specificity of the ProPneumo-
1, a newly developed commercial multiplex real-time PCR assay.
Methods: A total of 146 clinical respiratory specimens, collected from 1997 to 2007, suspected
of  C. pneumoniae or  M. pneumoniae infections were tested retrospectively. Nucleic acid was
extracted using an automated NucliSense easyMag (bioMerieux, Netherlands). We used a "Home-
brew" monoplex real-time assay as the reference method for the analysis of C. pneumoniae and
culture as the reference method for the analysis of M. pneumoniae. For discordant analysis
specimens were re-tested using another commercial multiplex PCR, the PneumoBacter-1 assay
(Seegene, Korea).
Results: Following discordant analysis, the sensitivity of the ProPneumo-1 assay for pathogens, C.
pneumoniae or M. pneumoniae, was 100%. The specificity of the ProPneumo-1 assay, however, was
100% for C. pneumoniae and 98% for M. pneumoniae. The limits of detection were 1 genome
equivalent (Geq) per reaction for pathogens, M. pneumoniae and C. pneumoniae. Due to the
multipex format of the ProPneumo-1 assay, we identified 5 additional positive specimens, 2 C.
pneumoniae in the M. pneumoniae-negative pool and 3 M. pneumoniae in the C. pneumoniae-negative
pool.
Conclusion:  The ProPneumo-1 assay is a rapid, sensitive and effective method for the
simultaneous detection of M. pneumoniae and C. pneumoniae directly in respiratory specimens.
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Background
Mycoplasma pneumoniae and Chlamydophila pneumoniae are
major causes of lower and upper respiratory tract infection
in adults and children [1-3] with high incidence occurring
among schoolchildren [4,5]. Both pathogens are difficult
to diagnose using conventional methods such as culture
and serology. Furthermore, respiratory infection may be
caused by one of several bacterial or viral pathogens that
share similar symptoms and clinical features. To over-
come difficulties in the detection of these pathogens, PCR
assays have been developed for the rapid detection and
identification of pathogens directly in respiratory samples
[6]. PCR assays are widely used in the clinical arena with
real-time PCR slowly replacing conventional PCR assays.
Several "home-brew" single target (monoplex) assays
have been utilized for the detection of numerous patho-
gens, including M. pneumoniae [7-9]. However, there are
multiple regulatory issues with the use of "home-brew"
assays and controversies exist as to their use in a diagnos-
tic laboratory setting. As commercial assays become more
available, there is a growing movement to replace "home-
brew" assays with commercially available products
[10,11]. As well, the monoplex PCR format is being
replaced by a multiplex one. The aim of this study was to
evaluate the analytical sensitivity and the diagnostic spe-
cificity and sensitivity of the ProPneumo-1 assay, a newly
developed commercial multiplex real-time PCR assay for
the simultaneous detection of M. pneumoniae and/or C.
pneumoniae DNA in clinical respiratory specimens.
Methods
Specimen collection and analysis by the reference method
Historically, suspected C. pneumoniae infections were
tested using a "home-brew" single target monoplex real-
time PCR assay [12] and suspected M. pneumoniae infec-
tions was tested using culture. As shown in Table 1, we
examined a total of 146 clinical respiratory specimens; of
which 58 were previously tested for C. pneumoniae using a
"home-brew" real-time PCR and 88 were previously tested
for M. pneumoniae using culture. Specimens were collected
in Ontario, between 1997 and 2007, from patients with
suspected C. pneumoniae or M. pneumoniae infections. The
types of specimen submitted for testing at the Central
Public Health Laboratory in Toronto, Ontario, including
patient's sex and age are described in Table 2 for M. pneu-
moniae, and 2B for C. pneumoniae. Specimens and
extracted nucleic acid were stored at -80°C until use.
DNA for "home-brew"monoplex real-time PCR was
extracted from specimens using the MagNA Pure LC
(Roche, Mannheim, Germany) as per manufacturer's
instructions. Specimens were tested using a "home-brew"
single target monoplex real-time PCR assay [12]. Real-
time amplification was carried out using the Roche Light
Cycler (Roche, Mannheim, Germany), as previously pub-
lished [12,13].
Mycoplsma pneumoniae
Clinical specimens from patients with suspected M. pneu-
moniae infection were cultured in PPLO medium contain-
ing thallium acetate, horse serum, yeast dialysate and
supplemented with amphotericin B (0.5 mg/ml), penicil-
lin G (100,000 u/ml) and nystatin (50,000 u/ml). Bipha-
sic culture flasks were inoculated with specimens,
incubated at 37°C and inspected daily for 4 weeks. The
organism was identified based on typical colonial mor-
phology on the agar medium and the change in the broth
color from red to orange then to yellow in the absence of
turbidity of the broth.
ProPneumo-1 and PneumoBacter-1 assays
Nucleic acid, for analysis by the ProPneumo-1 (Prodesse,
Waukesha, WI) or the PneumoBacter-1 (Seegene, Korea)
assay, was extracted using the easyMag NucliSense mag-
netic extraction (bioMerieux, Netherlands) [14]. Each
nucleic acid extract was amplified by both, the PromP-
neumo-1 and PneumoBacter-1 multiplex PCR assays. The
ProPneumo-1 assay was performed as per manufacturer's
instructions. Amplification and detection of the ProP-
neumo-1 test was performed on the ABI 7500 (Applied
Table 1: Summary of results for the evaluation of the ProPneumo-1 multiplex real-time PCR assay
C. pneumoniae M. pneumoniae
Monoplex ProPneumo-1 Culture ProPneumo-1
Positive specimens 11 14 42 41
Negative specimens 47 43 46 48
T o t a l 5 8 5 78 88 9
Note: The ProPneumo-1 assay detected 3 positive M. pneumoniae specimens in the C. pneumoniae-negative pool and 2 positive C. pneumoniae 
specimens in the M. pneumoniae-negative pool. Accordingly, 57 and 89 specimens were resolved for C. pneumoniae and M. pneumoniae, respectively 
by the ProPneumo-1 assay compared to 58 and 88 by the Monoplex assay and culture, respectively. The total number of specimens tested remains 
146.Annals of Clinical Microbiology and Antimicrobials 2009, 8:10 http://www.ann-clinmicrob.com/content/8/1/10
Page 3 of 9
(page number not for citation purposes)
Table 2: Overview of test results for a subset of M. pneumoniae patients




01 M 0.75 ETA Mpn + + +
02 M 32 NPS Mpn + + +
03 F 36 Sputum Mpn + + +
04 F 40 ETA Mpn + + +
05 M 26 Sputum Mpn + + +
06 F 56 Sputum Mpn + + +
07 F 72 Sputum Mpn + + +
08 F 26 BR wash Mpn + + +
09 F 7 TS Mpn + + +
10 M NA BAL Mpn + + +
11 F 11 NPS Mpn + + +
12 M 9 NPS Mpn + + +
13 NA NA NA Mpn + + +
14 M 3 NPS Mpn + + +
15 M 3 NPS Mpn + + +
16 M 6 NPS Mpn + + +
17 M 2 NPA Mpn + + +
18 M 13 NPS Mpn + + +
19 M 13 Sputum Mpn + + +
20 F 17 NPS Mpn + + +
21 F 13 NPS Mpn + + +
22 M 47 Sputum Mpn + + +
23 F 14 NPS Mpn + + +
24 F 5 NPS Mpn + + +
25 F 70 Sputum Mpn + + +
26 F 5 NPS Mpn + + +
27 M 44 Sputum Mpn + + +Annals of Clinical Microbiology and Antimicrobials 2009, 8:10 http://www.ann-clinmicrob.com/content/8/1/10
Page 4 of 9
(page number not for citation purposes)
Biosystems, Foster City, CA). For discordant analysis all
specimens, including concordant specimens, were re-
tested using the PneumoBacter-1 assay (Seegene, Korea).
PneumoBacter-1 is an agarose gel-based assay, amplifica-
tion was performed on the iCycler (Bio-Rad, Milpitas, CA)
and amplicons were imaged, following gel electrophore-
sis, as per manufacturer's protocols.
Experimental controls: external, internal and extraction 
controls
M. pneumoniae and C. pneumoniae quantified DNA con-
trols (Advanced Biotechnologies Inc., Columbia, MD)
were included in each assay as external positive controls.
For internal DNA control and to monitor for potential
PCR inhibitors, exogenous DNA was spiked into each
specimen. To monitor for the integrity of extracted nucleic
acid, all specimens were also tested for the presence of the
housekeeping gene, human glyceraldehyde phosphate
dehydrogenase (GAPDH) (Applied Biosystems. Foster
City, CA). Real-time amplification and detection of the
GAPDH gene sequence was performed on the ABI
7900HT (Applied Biosystems, Foster City, CA), as previ-
ously described [15,16]. This test was required to ascertain
the presence of nucleic acid in specimens, which tested
negative for C. pneumoniae or M. pneumoniae. For negative
controls, target nucleic acid and specimens were replaced
by PCR grade water in each PCR assay or nucleic acid
extraction run, respectively.
Limits of detection
The limits of detection for the assays described in this
study, ProPneumo-1 and PneumoBacter-1, were deter-
mined using 10 fold serial dilutions of quantified M. pneu-
moniae  and  C. pneumoniae DNA (Advanced
28 F 43 TS Mpn + + +
29 M 4 Sputum Mpn + + +
30 F 7 TS Mpn + + +
31 M 5 TS Mpn + + +
32 M 15 ETA Mpn + + +
33 M 10 TS Mpn + + +
34 M 8 TS Mpn + + +
35 F 23 Pharyngeal Mpn + + +
36 M 50 TS Mpn + + +
37 F 7 BAL Mpn + + +
38 NA NA NA Mpn + + +
39 F 61 Sputum Mpn + - -
40 F 7 NPS Mpn + - -
41 M 6 NPS Mpn + - -
42 M 18 TS Mpn + - -
43 M 9 NPS Mpn - + -
*44 NA NA NPS + +
*45 NA NA NPS + +
*46 NA NA NPS + +
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Biotechnologies Inc., Columbia, MD) in PCR-grade water.
Data analysis was carried out using SPSS 15.0 (SSPS Inc.,
Chicago, IL). Turn-around-times per assay were estimated
from a review of laboratory procedures and include time
from specimen reception to results reporting.
Definitions
The following definitions were used for analysis. Con-
cordant specimen: agreement between "home-brew"
assay result and Prodesse ProPneumo-1 assay result. Dis-
cordant specimen: disagreement between "home-brew"
assay result and Prodesse ProPneumo-1 assay result.
Resolved specimen: agreement in result, either positive or
negative between any two of the following assays; 1)
"home-brew" or culture, 2) ProPneumo-1, and 3) Pneu-
moBacter-1.
Results
Table 1 summarizes the results obtained for the evalua-
tion of the ProPneumo-1 real time multiplex PCR assay.
Overviews of the results obtained for subsets of M. pneu-
moniae and C. pneumoniae patients are presented in Table
2 and Table 3, respectively. Among patients who tested
positive for either pathogen, the ratio of male to female is
approximately the same and, with the majority of positive
patients being under the age of 20 years. Table 2 also dis-
plays the results obtained for each of the three tests used
to identify positive M. pneumoniae (A) or C. pneumoniae
(B) patients. Using a monoplex "home-brew" real-time
PCR as a reference in the analysis of C. pneumoniae and
culture as a reference in the analysis of M. pneumoniae, 14
and 41 specimens tested positive for C. pneumoniae and
M. pneumoniae, respectively by the ProPneumo-1 assay. As
shown in Table 1, 11 patients tested positive for C. pneu-
moniae  by the "home-brew" monoplex assay and 42
Table 3: Overview of test results for a subset of C. pneumoniae patients






01 M 13 BAL Cpn + + +
02 M 0.2 NPS Cpn + + +
03 F 10 BAL Cpn + + +
04 F 10 ETA Cpn + + +
05 F 2 BAL Cpn + + +
06 F 10 BAL Cpn + + +
07 F 63 NPS Cpn + + +
08 M 32 NPS Cpn + + +
09 F 63 TS Cpn + + +
10 F 19 NA Cpn + + +
11 M 48 BAL Cpn + - -
12 NA NA Autopsy Cpn - + +
13 NA NA Sputum Cpn - + +
**14 F 25 NPS + +
**15 F 44 NPS + +
Abbreviations: NA, not available; M, male; F, Female; NPS, nasopharyngeal swab; NPA, nasopharyngeal aspirate; BAL, bronchoalveolar lavage; ETA, 
endotracheal aspirate; TS, throat swab; BR, bronchial; Cpn, C. pneumoniae; Mpn, M. pneumoniae; PP-1, ProPneumo-1; PB-1, PneumoBacter-1. *, 
These specimens tested negative for C. pneumoniae in the monoplex assay but were defined positive for M. pneumoniae by the ProPneumo-1 and 
PneumoBacter-1 assays. **, These specimens tested negative for M. pneumoniae in culture but were defined positive for C. pneumoniae by the 
ProPneumo-1 and PneumoBacter-1 assays.Annals of Clinical Microbiology and Antimicrobials 2009, 8:10 http://www.ann-clinmicrob.com/content/8/1/10
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patients tested positive for M. pneumoniae by culture. Sim-
ilarly, 48 and 43 specimens were defined as negative in
the ProPneumo-1 assay, for M. pneumoniae and C. pneu-
moniae, respectively. Although, 42 positive M. pneumoniae
specimens were identified by culture and 41 by the ProP-
neumo-1assay, the identity of 8 positive specimens how-
ever, varies between the two methods (see Table 2).
Curiously, both assays the ProPneumo-1 and Pneumo-
Bacter-1 detected 5 additional positive specimens, 3 for
M. pneumoniae and 2 for C. pneumoniae in the C. pneumo-
niae-negative and M. pneumoniae-negative pool, respec-
tively.
The limit of detection of the ProPneumo-1 assay as deter-
mined by Probit regression (95% probability) was esti-
mated as follows: 1 genome equivalent (Geq)/reaction for
M. pneumoniae and 1 Geq/reaction for C. pneumoniae. The
limit of detection for PneumoBacter-1 was 1 Geq/reaction
for M. pneumoniae and 1 Geq/reaction for C. pneumoniae.
The turn-around-times, from specimen reception to
reporting, are as follows: ProPneumo-1, 6 hours; "home-
brew" monoplex PCR, 10 hours; PneumoBacter-1, 12
hours, and Mycoplasma culture, 4 weeks.
Diagnostic specificity and sensitivity
To determine the diagnostic specificity and sensitivity of
the ProPneumo-1 assay, results were scored against the
reference method ["home-brew" monoplex real-time PCR
for C. pneumoniae (see Table 4) and culture for M. pneumo-
niae (Table 5)]. To resolve discordant results, specimens
were re-tested using the multiplex PneumoBacter-1
method (Tables 4 and Table 5).
The ProPneumo-1 assay detected 14 positive C. pneumo-
niae specimens compared to 11 in the monoplex "home-
brew" assay, of which 1 specimen was false positive. Sim-
ilarly the ProPneumo-1 detected 43 negative C. pneumo-
niae specimens compared to 47 in the monoplex "home-
brew" assay, of which 2 specimens were false negative
(Table 1 and Table 3). Prior to discordant analysis, the
sensitivity and specificity of the ProPneumo-1 assay for C.
pneumoniae  was 91% and 96%, respectively (Table 4).
In the case of M. pneumoniae, ProPneumo-1 and culture
detected 42 and 41 positive specimens, respectively. How-
ever, 4 specimens scored positive by the culture method
(Table 1 and Table 2) and negative by the PCR method.
Likely, due to repeated freeze-thaw cycles and the long
storage period at -80°C (up to 10 years), these 4 speci-
mens are devoid of intact bacterial DNA and yielded neg-
Table 4: Specificity and sensitivity of the ProPneumo-1 assay for C. pneumoniae.
Before discordant analysis
C. pneumoniae Monoplex "Home-Brew" Results




Sensitivity = 91% Specificity = 96%
Following discordant analysis with PneumoBacter-1
C. pneumoniae Reference Method Results




Sensitivity = 100% Specificity = 100%Annals of Clinical Microbiology and Antimicrobials 2009, 8:10 http://www.ann-clinmicrob.com/content/8/1/10
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ative results in both PCR tests. Similarly, one specimen
appeared false positive by the ProPneumo-1 assay. We
suggest that this specimen is likely a true positive which
was not detected by the PneumoBacter-1 assay, likely due
to its gel-based format.
Prior to discordant analysis the sensitivity and specificity
of the ProPneumo-1 assay for M. pneumoniae was 95%
and 98%, respectively (Table 5). Following discordant
analysis by the PneumoBacter-1 multiplex assay and clas-
sification of specimens as per the definitions described
above, the sensitivity and specificity of the ProPneumo-1
assay for C. pneumoniae was 100% and 100%, respectively
(Table 4). The sensitivity and specificity of the ProP-
neumo-1 assay for M. pneumoniae, however, was 100%
and 98%, respectively (Table 5). Consistent with its mul-
tiplex format, the ProPneumo-1 assay detected 5 addi-
tional positive specimens, 2 C. pneumoniae in the M.
pneumoniae-negative pool and 3 M. pneumoniae in the C.
pneumoniae-negative pool.
Discussion
Early work in molecular diagnostics utilized technologies
that were considered to be site-developed or "home-brew"
in nature. Although these assays were considerable
advances at their time, they were often plagued by require-
ments for up-front research and development, quality
assurance, and laboratory accreditation issues [10,11]. As
a result, past molecular diagnostics for the clinical micro-
biology laboratory were often restricted to laboratories
that had the monetary and human resources to meet these
demands. In the last five years however, commercial prod-
ucts such as those identified in this manuscript have
allowed for the implementation of molecular diagnostics
without the up-front requirement for research and devel-
opment as well as simplified quality assurance steps.
The ProPneumo-1 assay demonstrated several strengths as
a commercial product for use in a wider range of clinical
microbiology laboratory settings outside of the reference
or highly resourced setting. First, this assay is a rapid, sen-
sitive and specific method that allows for the diagnosis of
C. pneumoniae and M. pneumoniae in a variety of clinical
specimens. Second, the fact that the Pro-Pneumo-1 assay
is a commercial product allows for simpler implementa-
tion in the diagnostic laboratory, and continued valida-
tion (e.g. quality assurance) when compared to "home-
brew" assays [10,11]. Third, the ProPneumo-1 assay is a
multiplex assay, which allows for multiple primer combi-
nations in one reaction, instead of multiple monoplex
Table 5: Specificity and sensitivity of the ProPneumo-1 assay for M. pneumoniae,
Before discordant analysis
M. pneumoniae Culture Results




Sensitivity = 95% Specificity = 98%
Following discordant analysis with PneumoBacter-1
M. pneumoniae Reference Method Results




Sensitivity = 100% Specificity = 98%Annals of Clinical Microbiology and Antimicrobials 2009, 8:10 http://www.ann-clinmicrob.com/content/8/1/10
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reactions. This not only makes the assay easier to perform
in a laboratory but also has the potential of utilizing less
patient specimen [17]. Indeed, using the ProPneumo-1
multiplex assay we detected 5 additional positive speci-
mens, 2 C. pneumoniae in the M. pneumoniae-negative pool
and 3 M. pneumoniae in the C. pneumoniae-negative pool.
There are several limitations to this study including its ret-
rospective nature. A further limitation of this study is the
relatively low number of C. pneumonia-positive specimens
analyzed. However, the number of specimens analyzed
represents the total complement of specimens available
from this region over a period of ten years. The authors
hope that further prospective analysis will allow for the
further characterization of this commercial assay.
Several studies have evaluated the use of multiplex PCR
for the detection of M. pneumoniae and C. pneumoniae in
clinical specimens [18-20]. These studies have used a vari-
ety of assays, patient populations and sample types, thus
proper validation and standardization are often lacking.
These factors make it difficult to compare different studies
although the finding has been generally consistent. A
study by Khanna and colleagues [19] described the Pneu-
moplex assays (standard and real-time PCR) that can
detect 5 pathogens, including M. pneumoniae and C. pneu-
moniae, in a single reaction. The diagnostic sensitivity of
the Pneumoplex assay was 100% and was defined by spik-
ing negative BAL specimens with bacterial DNA. The diag-
nostic specificity and sensitivity of the ProPneumo-1
assay, on the other hand, were determined in this study
directly from patient's specimens. Another study by
Ginevra and colleagues [20] described the triplex
Chlamylege assay, for the detection of Legionella, M. pneu-
moniae and C. pneumoniae. The diagnostic specificity of
the Chlamylege assay was also 100% and it was defined
by sequencing the DNA of discordant specimens. Com-
pared to our ProPneumo-1 study, fewer positive speci-
mens were used for the evaluation of the Chlamylege
assay (2 C. pneumoniae and 9 M. pneumoniae). However,
the lack of an of appropriate "gold standard" for the quan-
titative analysis of intracellular pathogens makes compar-
isons of the sensitivities of these different assays difficult.
In conclusion, the ProPneumo-1 real-time multiplex PCR
assay is a sensitive, specific, convenient and reliable tool
for the detection of atypical respiratory infection patho-
gens directly from respiratory tract specimens. The authors
believe that this product can be effectively implemented
in a wide variety of clinical microbiology settings outside
of reference and highly resourced laboratory settings.
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